ONWARD Medical enrols first participant in Empower BP trial

ONWARD Medical has announced the enrolment of the first participant in the Empower BP trial, a clinical study evaluating the ARC-IM system aimed at addressing blood pressure instability in patients with spinal cord injuries (SCI).

According to KBC Securities, this marks an important milestone in the further development of ONWARD’s technology platform. The analysts highlight that the company plans an interim efficacy analysis in the second half of 2026. Should the results indicate that fewer patients are required, the trial timeline could be accelerated.

In the near term, KBC Securities is looking ahead to the FY25 results, which are expected to provide more clarity on the commercial launch of the ARC-EX system. ONWARD reported that 70 devices were sold during the first nine months of 2025.

KBC Securities reiterates its BUY recommendation and maintains its price target of €8.9.